Diamedica Therapeutics Stock Performance
| DMAC Stock | USD 4.70 0.52 12.44% |
On a scale of 0 to 100, DiaMedica Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of 0.0619, which means not very significant fluctuations relative to the market. As returns on the market increase, DiaMedica Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding DiaMedica Therapeutics is expected to be smaller as well. Please check DiaMedica Therapeutics' mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether DiaMedica Therapeutics' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 12.44 | Five Day Return 14.63 | Year To Date Return 66.08 | Ten Year Return 301.71 | All Time Return (81.91) |
Last Split Factor 1:20 | Dividend Date 2018-11-15 | Last Split Date 2018-11-15 |
1 | Is Atossa Genetics Outperforming Other Medical Stocks This Year | 09/03/2024 |
2 | Acquisition by Gruis Kirsten L of 160000 shares of DiaMedica Therapeutics at 3.88 subject to Rule 16b-3 | 09/11/2024 |
3 | DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US9.05m | 10/08/2024 |
4 | ALGN Gears Up for Q3 Earnings What Lies Ahead for the Stock | 10/15/2024 |
5 | DiaMedica Therapeutics GAAP EPS of -0.15 in-line | 11/13/2024 |
6 | DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks | 11/14/2024 |
| Begin Period Cash Flow | 4.7 M | |
| Free Cash Flow | -18.8 M |
DiaMedica |
DiaMedica Therapeutics Relative Risk vs. Return Landscape
If you would invest 407.00 in DiaMedica Therapeutics on August 26, 2024 and sell it today you would earn a total of 63.00 from holding DiaMedica Therapeutics or generate 15.48% return on investment over 90 days. DiaMedica Therapeutics is currently generating 0.2661% in daily expected returns and assumes 3.0403% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than DiaMedica, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DiaMedica Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DiaMedica Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DiaMedica Therapeutics, and traders can use it to determine the average amount a DiaMedica Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0875
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DMAC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.04 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average DiaMedica Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DiaMedica Therapeutics by adding it to a well-diversified portfolio.
DiaMedica Therapeutics Fundamentals Growth
DiaMedica Stock prices reflect investors' perceptions of the future prospects and financial health of DiaMedica Therapeutics, and DiaMedica Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DiaMedica Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 151.14 M | ||||
| Shares Outstanding | 42.76 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 4.19 X | ||||
| EBITDA | (19.31 M) | ||||
| Net Income | (19.38 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 400 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Earnings Per Share | (0.56) X | ||||
| Market Capitalization | 200.97 M | ||||
| Total Asset | 54.16 M | ||||
| Retained Earnings | (115.56 M) | ||||
| Working Capital | 50.89 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
About DiaMedica Therapeutics Performance
By analyzing DiaMedica Therapeutics' fundamental ratios, stakeholders can gain valuable insights into DiaMedica Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DiaMedica Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DiaMedica Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 1.6 K | |
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about DiaMedica Therapeutics performance evaluation
Checking the ongoing alerts about DiaMedica Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DiaMedica Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (19.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks |
- Analyzing DiaMedica Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DiaMedica Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining DiaMedica Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DiaMedica Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DiaMedica Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DiaMedica Therapeutics' stock. These opinions can provide insight into DiaMedica Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |